Phase I/II results for Idec's IDEC-114

In a Phase I/II dose-ranging trial of IDEC-114 anti- B7-1 monoclonal antibody in 35 patients with psoriasis, IDPH reported that 40 percent of patients achieved at least a 50 percent reduction in PASI ...